The Supreme Court on Thursday sought a response from the Centre and others on a petition seeking sanction and release of the sum of Rs 14,20,00,000 required for the administration of Zolgensma Gene Therapy for a minor child.
Jaipur (Rajasthan) [India], May 23: Baby Hridyansh, suffering from Spinal Muscular Atrophy (SMA) type 2, successfully underwent Zolgensma gene therapy on Tuesday, 14th May at JK Lone Hospital, Jaipur. This therapy, known for its potential to dramatically improve the quality of life for SMA p
President Droupadi Murmu launched India's first home-grown gene therapy for cancer at IIT Bombay on Thursday. Speaking on the occasion, the President said that the launch of India's first gene therapy is a breakthrough in the battle against cancer.
22-month-old Hridyansh is fighting the most severe form of Spinal Muscular Atrophy (SMA) Type 2, which causes the wasting of voluntary muscles and impairs breathing.
Little Hridyansh is fighting the most severe form of Spinal Muscular Atrophy (SMA) Type 2, which causes the wasting of voluntary muscles and impairs breathing.
"In this study published in the journal Cardiovascular Research, we show that advanced heart failure can be treated to improve cardiac function in an animal model," said corresponding author Dr Tamer M. A. Mohamed.
A new study in mice suggests that replacing a dysfunctional gene may improve survival in some people with arrhythmogenic right ventricular cardiomyopathy (ARVC), a rare inherited disorder in which the heart's muscular walls gradually weaken, putting patients at risk of dangerous irregular he
A new study in mice suggests that replacing a dysfunctional gene may extend survival in some people with arrhythmogenic right ventricular cardiomyopathy (ARVC), a rare inherited disorder in which the muscular walls of the heart gradually weaken, putting patients at risk of dangerous irregula
Researchers have shown promising results about the potential of gene therapy to heal genetic disorders such as sickle cell disease, and the findings of this study, published in Nature Medicine, offer vital new insights into processes that occur in the body following treatment.
After rigorous testing on safety, quality and effectiveness Britain's Medicines and Healthcare products Regulatory Agency (MHRA) has authorised a world-first gene therapy, that will work to cure sickle-cell disease as well as B-thalassemia.
A recent review article Therapy summarises major milestones in the development of gene therapy medical products that have aided in the treatment of a large number of uncommon disorders. The essay also discusses the obstacles to the advancement of gene therapy for rare disorders.
Researchers used a noninvasive, ultrasound-based technique to investigate the safety and feasibility of gene delivery to numerous brain regions in rats, and their findings suggest that as more locations are opened, gene delivery effectiveness improves within each targeted site.